News | Biopsy Systems | June 09, 2016

UAB Receives Cutting-Edge Robot to Aid in Prostate Cancer Diagnosis, Treatment

University one of two U.S. beta sites to test new image-guided biopsy system

UAB, iSR'obot Mona Lisa, prostate cancer, image-guided biopsy

Jeffrey Nix, M.D., left, and Soroush Rais-Bahrami, M.D., with the iSR’obotTM Mona Lisa , a new image guided device for diagnosing prostate cancer. Image courtesy of UAB News.

UAB, robot, prostate cancer, MRI-ultrasound fusion biopsy, beta test

Rais-Bahrami works to further develop the iSR’obot Mona Lisa by providing feedback on utility of the deivice for potential clinical use. Image courtesy of UAB News.

June 9, 2016 — The University of Alabama at Birmingham (UAB) announced it is one of two beta sites in the United States that will receive the new iSR’obot Mona Lisa. The image-guided system provides urologic surgeons with a tool to diagnose prostate cancer earlier through accurate diagnosis and precise localization that may allow for targeted treatments in the future.

Lead investigator Soroush Rais-Bahrami, M.D., will determine the utility of the equipment for potential clinical use in the setting of the UAB Urologic Oncology Innovations Lab through a pilot pre-clinical project, “Phantom-Based Evaluation of a Novel Trans-Perineal Platform for Prostate Cancer Detection and Treatment.”

“As the only hospital in the Southeast to have the Mona Lisa robotic device, our team’s input on the device will help shape the future of prostate cancer diagnosis and treatment, not only for our patients at UAB but also patients worldwide,” said Rais-Bahrami, assistant professor in UAB’s Department of Urology and Department of Radiology. “Our feedback will help modify and make the already successful robot better as it launches in the United States for research and clinical implementation.”

The Mona Lisa robotic platform created by Biobot Surgical uses magnetic resonance imaging (MRI) and ultrasound fusion techniques to robotically guide biopsy of suspicious lesions. The fusion software helps with the localization of the needle when a biopsy procedure is performed, providing pinpoint accuracy. With UAB investigators, the device is being further developed to plan for minimally invasive focal therapy for treating prostate cancer in the future.

Ultimately, the Mona Lisa will be used for focal or targeted therapy through image guidance and treatment localization for prostate cancer. More than a thousand patients across Europe and Asia are already receiving biopsies with the Mona Lisa robotic device.

“In the United States, we are currently treating the entire prostate for cancer,” said Jeffrey Nix, M.D., assistant professor in UAB’s Department of Urology. “We have the capability to fuse MRI and ultrasound to identify the exact location of the cancer. We are excited about providing personalized care for each of our patients and look forward to the day that we can administer localized treatment with the use of the Mona Lisa.”

The Mona Lisa is being integrated as an investigation by a multidisciplinary team founded and co-directed by Rais-Bahrami and Nix. The UAB Program for Personalized Prostate Cancer Care combines experts from urology, radiology, radiation oncology, medical oncology and pathology to determine the best treatment pathway for each individual with prostate cancer.

UAB investigators are using phantom studies and 3-D personalized molds of prostates to prove the principle that biopsies with spacial accuracy of certain targeted regions can be performed.

After Biobot receives approval from the U.S. Food and Drug Administration (FDA) for the MRI-US Fusion software, UAB looks forward to beginning clinical trials that biopsy-qualified prostate cancer patients could benefit from the use of this device.

Biobot Surgical and BK Medical Systems provided support for the evaluation of this equipment.

For more information: www.uab.edu

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Triton College Launching Vascular Technology in Sonography Certificate Program
News | Ultrasound Imaging | January 09, 2019
Starting in spring 2019, Triton College’s Vascular Technology in Sonography Certificate Program will help working...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
First Arterial and Venous Atlas of the Human Brain Released
News | Neuro Imaging | January 02, 2019
January 2, 2019 — Imagine an atlas containing an image bank of the blood vessels of the...
MRI Effective for Monitoring Liver Fat in Obese Patients
News | Magnetic Resonance Imaging (MRI) | December 28, 2018
Magnetic resonance imaging (MRI) provides a safe, noninvasive way to monitor liver fat levels in people who undergo...
FDA Approves Exablate Neuro for Tremor-Dominant Parkinson's Treatment
Technology | Focused Ultrasound Therapy | December 21, 2018
Insightec announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication of...